# OnCo record neuroblastoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/neuroblastoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "neuroblastoma" ;
  schema:name "Neuroblastoma (paediatric)"@en ;
  schema:description "Neuroblastoma is a childhood nerve-cell cancer where anti-GD2 antibodies and, recently, GD2 CAR-T have improved survival in high-risk disease."@en ;
  schema:url <https://onco.cc/cancers/neuroblastoma/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Neuroblastoma> ;
  owl:sameAs <http://www.wikidata.org/entity/Q938205> ;
  schema:citation <https://en.wikipedia.org/wiki/Neuroblastoma> ;
  onco:tag "paediatric", "spike" ;
  onco:related <https://onco.cc/roadmaps/paediatric-oncology-roadmap/>, <https://onco.cc/cancers/wilms-tumor/>, <https://onco.cc/cancers/hepatoblastoma/>, <https://onco.cc/cancers/retinoblastoma/>, <https://onco.cc/cancers/paediatric-germ-cell-tumours/>, <https://onco.cc/pairings/anti-gd2-plus-chemo-relapse/>, <https://onco.cc/pairings/il2-anti-gd2-caution/> ;
  onco:technologies <https://onco.cc/technologies/car-t/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/radioligand-therapy/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/tandem-transplant/>, <https://onco.cc/technologies/mibg-theranostics/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/> ;
  onco:targets <https://onco.cc/targets/alk/>, <https://onco.cc/targets/gd2/> ;
  onco:drugs <https://onco.cc/drugs/isotretinoin/> ;
  onco:companies <https://onco.cc/companies/y-mabs/>, <https://onco.cc/companies/us-worldmeds/>, <https://onco.cc/companies/childrens-oncology-group/> ;
  onco:institutions <https://onco.cc/institutions/mskcc/>, <https://onco.cc/institutions/dana-farber/>, <https://onco.cc/institutions/stanford/>, <https://onco.cc/institutions/city-of-hope/> ;
  onco:terms <https://onco.cc/terms/inrg-staging/>, <https://onco.cc/terms/mycn-amplification/>, <https://onco.cc/terms/efs/>, <https://onco.cc/terms/adcc/>, <https://onco.cc/terms/crs/> ;
  onco:trials <https://onco.cc/trials/ccss/>, <https://onco.cc/trials/nct04724369/> ;
  onco:journals <https://onco.cc/journals/journal-of-pediatric-hematology-oncology/>, <https://onco.cc/journals/pediatric-hematology-and-oncology/> ;
  onco:pipeline <https://onco.cc/technologies/armored-car/>, <https://onco.cc/trials/anbl1531/>, <https://onco.cc/drugs/i131-mibg/>, <https://onco.cc/drugs/lorlatinib/>, <https://onco.cc/trials/gd2-cart01/>, <https://onco.cc/ideas/idea-gd2-car-t-frontline-consolidation/>, <https://onco.cc/ideas/idea-mfbg-pet-replaces-mibg/>, <https://onco.cc/technologies/mibg-theranostics/>, <https://onco.cc/drugs/eflornithine/>, <https://onco.cc/drugs/naxitamab/>, <https://onco.cc/pairings/anti-gd2-plus-chemo-relapse/>, <https://onco.cc/technologies/tandem-transplant/>, <https://onco.cc/companies/y-mabs/> ;
  onco:standardOfCare <https://onco.cc/drugs/lorlatinib/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/terms/inrg-staging/>, <https://onco.cc/technologies/ultrasound/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/terms/inrg-staging/>, <https://onco.cc/trials/anbl1531/>, <https://onco.cc/drugs/i131-mibg/>, <https://onco.cc/drugs/lorlatinib/>, <https://onco.cc/drugs/dinutuximab/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/trials/anbl17p1/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/proton-therapy/>, <https://onco.cc/technologies/tandem-transplant/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/trials/anbl0532/>, <https://onco.cc/trials/hr-nbl1/>, <https://onco.cc/drugs/dinutuximab/>, <https://onco.cc/trials/anbl0032/>, <https://onco.cc/drugs/eflornithine/>, <https://onco.cc/trials/nmtrc003/>, <https://onco.cc/pairings/il2-anti-gd2-caution/>, <https://onco.cc/drugs/dinutuximab/>, <https://onco.cc/drugs/naxitamab/>, <https://onco.cc/trials/naxitamab-201/>, <https://onco.cc/drugs/i131-mibg/>, <https://onco.cc/drugs/lorlatinib/>, <https://onco.cc/trials/gd2-cart01/>, <https://onco.cc/pairings/anti-gd2-plus-chemo-relapse/>, <https://onco.cc/trials/anbl1221/>, <https://onco.cc/technologies/cardio-oncology/> .